This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pedrinelli, R. Articles by Mariani, M. Search for Related Content PubMed PubMed Citation Articles by Pedrinelli, R. Articles by Mariani, M.

(Hypertension. 1998;32:318-323.)
© 1998 American Heart Association, Inc.

Scientific Contributions

Transvascular and Urinary Leakage of Albumin in Atherosclerotic and Hypertensive Men

Roberto Pedrinelli; Giuseppe Penno; Giulia Dell'Omo; Simona Bandinelli; Davide Giorgi; Vitantonio Di Bello; Monica Nannipieri; Renzo Navalesi; ; Mario Mariani

From the Dipartimento di Cardiologia, Angiologia, e Pneumologia (R.P., G.D.'O., M.M.), Medicina Interna (D.G., V. Di B.), e Diabetologia (G.P., S.B., M.N., R.N.), Università di Pisa, Pisa, Italy.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—Increased urine albumin is associated with atherosclerotic disease and predicts cardiovascular morbidity and mortality in nondiabetic populations. This finding is frequently postulated to reflect the impact of atherosclerotic damage on glomerular and systemic capillary permeability, an interesting but as yet untested hypothesis. The transcapillary escape rate of albumin (TERalb, the 1-hour decline rate of intravenous ¹²⁵I-albumin, a measure of capillary macromolecular permeability), albuminuria, lipid levels, echocardiographic wall thickness, and insulin responses to oral glucose were measured in 30 untreated dipstick-negative lean men and clinically stable atherosclerotic peripheral vascular disease; tolerance to oral glucose was a requirement for inclusion in the study. Because hypertension per se might influence TERalb, the sample included either normotensive (n=18, 118±6/72±7 mm Hg) or hypertensive (n=12, 141±7/84±6 mm Hg by 24-hour blood pressure monitoring) arteriopathic patients; 11 normal age- and gender-matched subjects (121±7/76±5 mm Hg) were used as control subjects. TERalb was higher in patients (10.7±3.2 versus 7.4±1.7%/h, P<0.013), a difference that persisted after postload glucose, insulin, and lipid levels were accounted for by covariance analysis; atherosclerosis and hypertension together did not further impair vascular permeation to albumin. In contrast with TERalb, albuminuria was elevated only in the hypertensive subgroup; the 2 variables showed no relationship, even when the data were analyzed separately in normotensive and hypertensive subgroups. Urine albumin correlated positively with 24-hour blood pressure and wall thickness. Thus, systemic capillary permeability is altered in nondiabetic atherosclerotic patients independently from blood pressure levels, but this abnormality is not reflected by proportionate changes in albuminuria.

Key Words: capillary permeability • albuminuria • atherosclerosis • hypertension, essential • vascular diseases

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Minute increments in UAE (microalbuminuria) are associated with greater prevalence of atherosclerotic vascular disease and predict all-cause and coronary disease morbidity and mortality not only in subjects with type 1 and type 2 diabetes (see References 1 and 2^{1 2} for recent data) but also unselected populations,^{3 4 5 6 7} as well as essential hypertensive patients.^{8 9 10} Thus, albuminuria may be a marker of generalized disease in the vascular wall, but the precise reasons for this relationship remain elusive. It is possible that the glomerular albumin leak reflects a widespread atherosclerotic-mediated capillary vasculopathy affecting extrarenal organs.¹¹ This frequently quoted speculation seems valid for type 1 and type 2 diabetic patients^11,12; whether it applies also to nondiabetic subjects is still unclear. For this reason, we measured the TERalb (the fraction of the intravascular mass of albumin going through the vascular bed per unit of time, a parameter that estimates the integrity of systemic capillary permeability)¹³ and UAE in glucose-tolerant patients with atherosclerotic PVD. Because elevated BP may influence both UAE¹⁴ and TERalb,¹⁵ we stratified our sample according to the presence of normotension or hypertension.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Subjects
All subjects were white men. The patient group was composed of 30 patients with atherosclerotic PVD and stable intermittent claudication (pain-free walking distance >200 m on a treadmill). Angiography showed typical iliac and/or femoral atherosclerotic lesions (diffuse plaques causing stenosis and/or occlusion at arterial branch points) in all patients combined with crural alterations in some. Subjects had fasting blood glucose levels <6.7 mmol/L (120 mg/dL), HbA₁c <6%, and normal oral glucose tolerance (2-hour post–oral glucose load <7.8 mmol/L, 140 mg/dL). Serum creatinine was <110 µmol/L (1.2 mg/dL) and total serum cholesterol <7.8 mmol/L (300 mg/dL); there was normal urinary sediment, no urinary tract infection, BMI <30 kg/m², and no evidence or history of congestive heart failure, advanced chronic obstructive pulmonary disease, previous amputation, pain at rest, or ischemic trophic ulcers or gangrene. Eighteen patients were normotensive on the basis of several normal casual BP determinations confirmed by 24-hour ABPM (<130/80 mm Hg¹⁶) in the absence of antihypertensive treatment, and 12 mild-moderate hypertensive subjects were diagnosed on the basis of repeated casual BP determinations >140/90 but <160/110 mm Hg as outpatients. Angiograms had shown normal renal arteries, and renal ultrasound scanning showed normal-sized kidneys and no evidence of cortical scarring or obstructive uropathy; routine clinical and hematological examinations excluded other secondary forms of hypertension. Hypertensive patients (n=6 never-treated) were studied after 2-week drug withdrawal (calcium channel blockers, angiotensin-converting enzyme inhibitors, or both). No patient had ever taken lipid-lowering drugs, and all had received either ticlopidine or aspirin. Eleven subjects with normal findings for physical examination, routine blood and urinary tests, BP, ECG, abdominal echography, and ankle/brachial index were the control subjects. Experimental evaluations were completed in a 2-week period. A consistent portion of our patients could not offer reliable data regarding family history of hypertension and diabetes; therefore, we did not pursue this issue any longer.

According to institutional guidelines, subjects were aware of the investigational nature of the study and agreed to participate. The study was carried out in accordance with the Declaration of Helsinki, and the protocol was approved by the local ethics committee.

Experimental Procedures
TERalb
TERalb was measured between 2 and 4 PM after a 4- to 6-hour fast and no tea, coffee, alcohol, or tobacco from the early morning. After subjects rested for 30 minutes in the supine position, ¹²⁵I-labeled human serum albumin (6 to 8 µCi, 222 to 296 kBq, SARI-125 A-2; SORIN Biomedica) was injected as a bolus, and blood was withdrawn from the contralateral arm every 5 minutes during the hour following the injection. Radioiodinated albumin was freshly purified from free ¹²⁵I, eluting the high-molecular-weight components into columns containing Sephadex G-25 mol/L (column PD-10; Pharmacia); free ¹²⁵I content in the injected dose was <1%. Radioactivity was measured (Cobra 5000 gamma counter; Hewlett-Packard) in duplicate in whole blood samples centrifuged for 10 minutes at 3000g. Counting time was 40 minutes with a percentage of error <20%; hematocrit level (Coulter Counter 55; Coulter Electronics) was determined in each sample. Serum albumin was measured by immunonephelometry (Behring Laser Nephelometer System; interassay variation coefficient, 5.2%).

Urinary Albumin Excretion
UAE was measured by nephelometry (Behring; limit of detection: 0.1 mg/dL; interassay variation coefficient: 3.5%). To minimize the confounding influence of daily physical activity and to facilitate the procedure, urine was collected from 8 PM to 8 AM during 3 consecutive days.

24-Hour ABPM and Cardiovascular and Renal Function Parameters
ABPM (24-hour) was performed using an oscillometric monitor (SpaceLabs 90207, SpaceLabs) on a regular work day. Recording began between 8:30 and 9 AM, with readings every 15 minutes until midnight and every 30 minutes from midnight to 8 AM.

Ankle-brachial index (the ratio between systolic BP measured at the brachial and bilateral posterior tibial artery) was measured by Doppler (Stereodop, Promelec).

Wall thickness and chamber volumes were measured by monodimensional and bidimensional echocardiograms (Hewlett-Packard Sonos 1000) with 2.5- and 3.5-MHz transducers.

Serum and urine (the same samples used for UAE determination) creatinine levels were assayed by standard colorimetric methods.

Metabolic Parameters
Anthropometric measurements (height and weight) were made after each participant had removed his shoes and upper garments. Blood samples were obtained between 8 and 9 AM after an overnight fast and 15 minutes of supine rest. A glucose tolerance test was performed in the morning with a 75-g glucose load. Individuals were asked to fast for 12 to 14 hours before the test, and specimens for plasma glucose and insulin were drawn basally and at 0.5, 1, 1.5, and 2 hours after administration of the glucose load. Plasma glucose was measured by the gluco-oxidase method, and plasma insulin by radioimmunoassay (Biosource, no cross-reactivity with human proinsulin). Chol_TOT, Chol_HDL, and triglyceride levels were assessed by enzymatic colorimetric techniques (Boehringer-Mannheim); Chol_LDL was calculated as [Chol_TOT-(Chol_HDL+triglyceride/5)].

Data Analysis
Plasma ¹²⁵I-albumin concentration (cpm/mL) was plotted on a semilogarithmic scale, and the transcapillary escape rate (%/h) was calculated from the monoexponential disappearance rate constant of the ¹²⁵I curve from 10 to 60 minutes.¹³ UAE (µg/min) was the average of 3 consecutive collections (mean variation coefficient of triplicate measurements, 24%). According to standard criteria, microalbuminuria was defined as a value between 20 and 200 µg/min. ABPM values were the mean of the overall 24-hour readings after artifact editing. Plasma volume (mL/1.73 m²) was determined by retropolation to zero time of the disappearance curve corrected for the injected dose of tracer obtained by weighing the syringes before and after the injection. Two-hour area under the curve of postload plasma insulin and glucose was calculated by the trapezoidal rule. BMI (body weight/surface area, squared) and creatinine clearance (mean variation coefficient of triplicate measurements, 17%) were derived according to standard formulas.

Statistics
Log transformation was applied to TERalb, UAE, plasma insulin, and triglycerides because the raw data were not distributed normally. Descriptive statistics were mean±SD or medians and ranges for skewed data. Differences among means were tested by 1-way ANOVA, correcting for potential confounders by ANCOVA. A multiple range test was used to evaluate differences between means. Intraindividual association of variables in hypertensive subjects was tested by Pearson's correlation coefficients. Statistical significance was set at P<0.05. Calculations were performed using Statgraphics Plus (Manugistic Inc, release 1997).

	Results

Top Abstract Introduction Methods Results Discussion References

 
Age and prevalence of current smokers did not differ among the 3 groups; 24-hour ABPM in normotensive PVD patients was closely comparable to that of normal subjects and higher in hypertensive arteriopathic patients, as expected. Ankle-brachial index, a measure of hemodynamic severity,¹⁷ was similarly reduced in patients. Myocardial walls were thicker in hypertensive subjects; cardiac and renal function was normal (Table 1).

View this table: [in this window] [in a new window]   Table 1. Age, Smoking Habits, 24-Hour BP, and Cardiovascular and Renal Parameters in Controls and Normotensive and Hypertensive Atherosclerotic Patients

Atherogenic lipid levels were elevated in patients; levels of Chol_HDL and HbA₁c did not differ (Table 2).

View this table: [in this window] [in a new window]   Table 2. Levels of Lipid, Glucose, Insulin, Plasma Volume, Hematocrit, and Serum Albumin in Controls and Normotensive and Hypertensive Atherosclerotic Patients

Patients showed hyperinsulinemia and hyperglycemia after oral glucose, a trend more evident in hypertensive subjects, who also showed greater BMI (P<0.08) (Table 2).

TERalb
TERalb was higher (10.7±3.2 versus 7.4±1.7%/h, P<0.013) in atherosclerotic patients. The difference persisted after accounting for BP, postload glucose and insulin, lipid level, and UAE level by ANCOVA (Table 3). Serum albumin concentration, hematocrit level, and plasma volume were comparable in the 3 groups (Table 2).

View this table: [in this window] [in a new window]   Table 3. ANCOVA For TERalb

TERalb values did not differ between normotensive and hypertensive patients (Figure 1, left).

View larger version (10K): [in this window] [in a new window]   Figure 1. Increased TERalb in normotensive (NT&ATH, n=18) and hypertensive (EH&ATH, n=12) arteriopathic patients compared with age- and gender-matched control subjects (n=11; P<0.01 for both) (left) as opposed to elevated (P<0.004) UAE only in hypertensive patients (right). To take into account the skewed UAE data distribution, results are presented as box-and-whisker plots: the central box encloses the middle 50% of the data; the horizontal line inside the box represents the median, and the mean is plotted as a cross. Vertical lines (whiskers) extend from each end of the box and cover 4 interquartile ranges. Points identify outliers. For statistics, see text.

Urinary Albumin Excretion
UAE was similar in normotensive arteriopathic patients and control subjects and was elevated (P<0.004) in the hypertensives (Figure 1, right), in whom microalbuminuria was present in 5 subjects (median UAE, 125 µg/min; range, 26 to 198 µg/min).

Correlations
TERalb and UAE values were unrelated (Figure 2). The same negative result was obtained in the 2 patient subgroups (normotensive arteriopathic patients: r=-0.14, P<0.57; hypertensive arteriopathic patients: r=-0.37, P<0.24) when analyzed separately.

View larger version (14K): [in this window] [in a new window]   Figure 2. Absence of a relationship between TERalb (abscissa) and UAE (ordinate, log scale). The plot shows data of control subjects (*, n=11) and normotensive (, n=18) and hypertensive (x, n=12) arteriopathic patients. The correlation coefficient was –0.14, P<0.4; n=41.

TERalb did not correlate (n=41) with any of the numeric parameters listed in Tables 1 and 2, including systolic (r=0.14, P<0.4) and diastolic (r=-0.08, P<0.5) ABPM. In the same set of data, UAE correlated directly with values for ABPM (systolic: r=0.50, P<0.0001; diastolic: r=0.53, P<0.0001) and wall thickness (interventricular septum thickness: r=0.50, P<0.0008; posterior wall thickness: r=0.44, P<0.004).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The two main and original results of this cross-sectional case-control study carried out in glucose-tolerant men with normal renal function and comparable prevalence of active smokers were (1) increased TERalb in atherosclerotic patients compared with normal age-matched control subjects and (2) dissociated behavior of UAE and TERalb.

Increased TERalb in Atherosclerotic Patients
Our data identify a defect that is likely localized at the capillary level where most of the albumin permeation takes place,¹³ although the contribution to this increase from various organs and tissues with different permeability cannot be identified precisely. This result confirms the existence of a systemic microvascular involvement in atherosclerotic PVD, an issue approached by other investigators by evaluating the vasorelaxant potential of resistance and conduit lower limb arteries,¹⁸ both scarcely representative of the most distal segments of the systemic microcirculation. Increased transvascular protein transport may be due to (1) increased transmural pressure difference, (2) increased area of the microcirculatory bed, and (3) increased microvascular permeability.¹³ The first factor was unlikely to play any major role because the abnormal microvascular albumin leakage characterized patients with normal BP, in whom preserved cardiac function also allowed the exclusion of an influence of increased postcapillary resistance.¹⁹ Quite surprisingly in the light of previous results,^{15 20 21} hypertension combined with atherosclerosis was not associated with further additional increments in capillary permeability. However, ex post facto calculation of statistical power showed that our sample size (n=12 hypertensive versus n=18 normotensive) had the statistical power to safely exclude (ß<0.20) only differences 3%/h. Thus, the negative result could be due to insufficient statistical power, but other explanations are conceivable. For example, TERalb may have a ceiling or be sensitive only to frankly elevated pressor regimens¹⁵ as opposed to the mild-moderate values present in our hypertensive patients.²² Type of previous antihypertensive medication²³ and/or length of treatment might also affect the transvascular leakage of albumin, but we cannot deny or support any of the above possibilities. Increased microcirculatory area due to open-ing of nonperfused capillaries could theoretically increase TERalb, a hypothesis not to be refuted a priori, even though the data on capillary rarefaction in hypertension²⁴ suggest the opposite inference, if anything. Overall, exaggerated capillary permeability seems a more likely explanation for the increased transvascular albumin leakage shown in this group of atherosclerotic patients. Changed permeability of the vascular wall due to reduced concentration of anionic glycosaminoglycans is possible,¹¹ and altered permeability due to systemic atherosclerotic endothelial dysfunction is also conceivable.²⁵ Yet, the available evidence on this topic has been gathered mainly through evaluation of vasorelaxation to nitric oxide–releasing drugs; how TERalb relates to it is unknown. As reported previously,^{21 23} no significant correlation was found with total and LDL cholesterol levels, suggesting that lipids may not influence capillary permeation of albumin. We also evaluated the insulinemic response to oral glucose, since insulin may play a role in the transfer of macromolecules from the blood to the extracellular space after food intake.²⁶ Endogenous insulin levels did not appear to influence TERalb, in indirect agreement with the ineffectiveness of exogenous infusion of the hormone on vascular permeability.²⁷ It was also of interest that the emerging pattern of hyperinsulinemia combined with slight, albeit still normal, hyperglycemia in our arteriopathic patients confirmed previous data suggestive of some defect in glucose disposal in this clinical condition.²⁸

Dissociated Behavior of UAE and TERalb
Coexistence of normal UAE with elevated TERalb and lack of any intraindividual relationship between the 2 parameters does not support the concept based on inferential evidence²⁹ of increased urine albumin as a direct reflection of altered systemic microvascular permeability, a conclusion limited to permeability quantified through TERalb determination and to nondiabetic patients with atherosclerotic PVD. On the basis of these data, one is led to postulate an indirect link between microalbuminuria and atherosclerosis through adverse changes in cardiovascular risk factors. As a matter of fact, microalbuminuria was found only in the hypertensive components of this sample, and in this as well as our previous studies,³⁰ UAE correlated positively with both 24-hour ABPM and wall thickness, a long-term sensor of afterload. Inappropriate matching for BP levels might explain why Jensen³¹ found parallel elevation in UAE and TERalb in his pooled series of normotensive and hypertensive patients with severe atherosclerotic vascular disease. Furthermore, exaggerated insulin response and lower tolerance to glucose load (in itself suggestive of a greater insulin resistance³²) did characterize our hypertensive arteriopathic patients in whom microalbuminuria was also highly prevalent. This behavior may suggest that, as in non–insulin-dependent diabetic subjects,³³ renal excretion of albumin increases for still-unclear reasons in the presence of greater degrees of insulin resistance. However, coexisting hypertension and insulin resistance could not account for the association of microalbuminuria with carotid atherosclerosis in recent studies.^{34 35} Furthermore, the systemic implications of albuminuria are underlined by accruing evidence showing independent links between UAE and vascular disease in nondiabetic subjects.^{3 4 5 6 7} Several possibilities can be imagined to reconcile the initial working hypothesis with our negative results. Due to the complex regulation of intraglomerular hemodynamics, an abnormal permeability might still be compensated for by other control mechanisms, such as modulation of afferent and efferent arteriolar tone and/or modifications of the mesangial cell contractile tone.³⁶ Thus, microalbuminuria could identify only those more advanced systemic vasculopathies bound to trigger new clinical events,^{3 4 5 6 7 8 9 10} while TERalb could be sensitive even to milder, more stable forms of disease. This assumption is reasonable because the mutual relationships and the exact interpretation of the different indices of vascular damage are still undetermined and most likely not uniform. For example, the transvascular leakage of albumin, a variable of still-unknown prognostic power, was increased in non–insulin-dependent diabetics both with and without nephropathy.³⁷ On the other hand, von Willebrand factor level, a recognized predictor of cardiovascular events³⁸ and a circulating marker of endothelial dysfunction,³⁹ was elevated only in microalbuminuric subjects with either essential hypertension⁴⁰ or diabetes.³⁷ Second, abnormalities in TERalb and UAE might react with different time rates in response to the development of microvascular atherosclerotic damage; our patients were recruited cross-sectionally at unknown but most likely variable points of the individual clinical course. Third, albuminuria and TERalb might identify different coexisting kinds of systemic vascular impairment such as endothelial dysfunction⁴⁰ versus abnormal macromolecular permeability of the extracellular matrix for anionic proteins,¹¹ respectively, a problem never addressed so far.

In conclusion, systemic capillary permeability is altered in nondiabetic atherosclerotic patients independently from BP levels, but this abnormality is not reflected by proportionate changes in albuminuria. However, more studies are needed to understand in full the mechanisms that connect microalbuminuria and vascular disease.

	Selected Abbreviations and Acronyms

 

ABPM = ambulatory blood pressure monitoring BMI = body mass index BP = blood pressure CholHDL = high-density-lipoprotein cholesterol CholLDL = low-density-lipoprotein cholesterol CholTOT = total cholesterol HbA1c = glycated hemoglobin PVD = peripheral vascular disease UAE = urinary albumin excretion

	Acknowledgments

 
This work was financed in part through Fondi di Ateneo (AF97).

	Footnotes

 
Reprint requests to Roberto Pedrinelli, MD, Dipartimento di Cardiologia, Angiologia, e Pneumologia, Università di Pisa, Pisa 56100, Italy.

Received January 15, 1998; first decision February 19, 1998; accepted March 4, 1998.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Deckert T, Yokoyama H, Mathiesen E, Ronn B, Jensen T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen JS. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. BMJ. 1996;312:871–874.[Abstract/Free Full Text]

2. Beilin J, Stanton KG, McCann VJ, Knuiman MW, Divitini ML. Microalbuminuria in type 2 diabetes: an independent predictor of cardiovascular mortality. Aust N Z J Med. 1996;26:519–525.[Medline] [Order article via Infotrieve]

3. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in nondiabetic subjects. Lancet. 1988;2:530–533.[Medline] [Order article via Infotrieve]

4. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as a predictor of increased mortality in elderly people. BMJ. 1990;300:297–300.

5. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation. 1995;91:831–837.[Abstract/Free Full Text]

6. Gorgels WJMJ, Van der Graaf Y, Hjemdahl P, Kortlandt W, Collette HJA, Erkelens DW, Banga JD. Urinary excretion of high molecular weight ß-thromboglobulin and albumin are independently associated with coronary heart disease in women, a nested case-control study of middle-aged women in the Diagnostic Onderzoek Mammacarcinoom (DOM) cohort, Utrecht, Netherlands. Am J Epidemiol. 1995;142:1157–1164.[Abstract/Free Full Text]

7. Jensen JS, Borch-Johnsen K, Feldt-Rasmussen B, Appleyard M, Jensen G. Urinary albumin excretion and history of acute myocardial infarction in a cross-sectional population study of 2,613 individuals. J Cardiovasc Risk. 1997;4:121–125.[Medline] [Order article via Infotrieve]

8. Agewall S, Persson B, Samuelsson O, Ljungman S, Herlitz H, Fagerberg B. Microalbuminuria in treated hypertensive men at high risk of coronary disease. J Hypertens. 1993;11:461–469.[Medline] [Order article via Infotrieve]

9. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens. 1996;14:223–228.[Medline] [Order article via Infotrieve]

10. Ljungman S, Wikstrand J, Hartford M, Berglund G. Urinary albumin excretion: a predictor of risk of cardiovascular disease—a prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens. 1996;9:770–778.[Medline] [Order article via Infotrieve]

11. Deckert T, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T. Microalbuminuria: implications for micro- and macrovascular disease. Diabetes Care. 1992;15:1181–1191.[Abstract]

12. Nannipieri M, Pilo A, Rizzo L, Penno G, Rapuano A, Navalesi R. Increased transcapillary escape rate of albumin in microalbuminuric type II diabetic patients. Diabetes Care. 1995;18:1–9.[Abstract]

13. Parving HH. Microvascular permeability to plasma proteins in hypertension and diabetes mellitus in man: on the pathogenesis of hypertensive and diabetic microangiopathy. Dan Med Bull. 1975;22:217–233.[Medline] [Order article via Infotrieve]

14. Pedrinelli R. Microalbuminuria in hypertension. Nephron. 1996;73:499–505.[Medline] [Order article via Infotrieve]

15. Parving HH, Gyntelberg F. Transcapillary escape rate of albumin and plasma volume in essential hypertension. Circ Res. 1973;32:643–651.[Abstract/Free Full Text]

16. Mancia G, Sega R, Bravi C, De Vito G, Valagussa F, Cesana A, Zanchetti A. Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens. 1995;13:1377–1390.[Medline] [Order article via Infotrieve]

17. Kiekara O, Riekkinen H, Soimakallio S, Lansimies E. Correlation of angiographically determined reduction of vascular lumen with lower-limb systolic pressures. Acta Chir Scand. 1985;151:437–440.[Medline] [Order article via Infotrieve]

18. Liao JK, Bettmann MA, Sandor T, Tucker JI, Coleman SM, Creager MA. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res. 1991;68:1027–1034.[Abstract/Free Full Text]

19. Hesse B, Parving HH, Lund-Jacobsen H, Noer I. Transcapillary escape rate of albumin and right atrial pressure in chronic congestive heart failure before and after treatment. Circ Res. 1976;39:358–362.[Abstract/Free Full Text]

20. Parving HH, Jensen HAE, Westrup M. Increased transcapillary escape rate of albumin and IgG in essential hypertension. Scand J Clin Lab Invest.. 1977;37:223–227.[Medline] [Order article via Infotrieve]

21. Nannipieri M, Penno G, Rizzo L, Pucci L, Bandinelli S, Mattei P, Taddei S, Salvetti A, Navalesi R. Transcapillary escape rate of albumin in type II diabetic patients. Diabetes Care. 1997;20:1019–1026.[Abstract]

22. Norgaard K, Jensen T, Feldt-Rasmussen B. Transcapillary escape rate of albumin in hypertensive patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1993;36:57–61.[Medline] [Order article via Infotrieve]

23. Nielsen FS, Rossing P, Gall MA, Smidt UM, Chen JW, Sato A, Parving HH. Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. Scand J Clin Lab Invest. 1997;57:427–434.[Medline] [Order article via Infotrieve]

24. Sullivan JM, Prewitt RL, Josephs JA. Attenuation of the microcirculation in young patients with high-output borderline hypertension. Hypertension. 1983;5:844–851.[Abstract/Free Full Text]

25. Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, Creager MA, Selwin AP, Ganz P. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol. 1995;75:71b–74b.

26. Hilsted J, Christensen NJ. Dual effect of insulin on plasma volume and transcapillary albumin transport. Diabetologia. 1992;35:99–103.[Medline] [Order article via Infotrieve]

27. Catalano C, Muscelli E, Quinones A, Baldi S, Masoni A, Gibb I, Torffvit O, Seghieri G, Ferrannini E. Effect of insulin on systemic and renal handling of albumin in nondiabetic and NIDDM subjects. Diabetes. 1997;46:868–875.[Abstract]

28. Welborn TA, Breckenridge A, Rubinstein AH, Dollery CT, Fraser TR. Serum insulin in essential hypertension and in peripheral vascular disease. Lancet. 1966;1:1336–1337.[Medline] [Order article via Infotrieve]

29. Pedrinelli R. Microalbuminuria: a marker of systemic vascular damage? Nephrol Dial Transplant. 1997;12:379–381.[Free Full Text]

30. Pedrinelli R, Di Bello VA, Catapano G, Talarico L, Materazzi F, Santoro G, Giusti C, Mosca F, Melillo E, Ferrari M. Microalbuminuria is a marker of left ventricular hypertrophy but not hyperinsulinemia in nondiabetic atherosclerotic patients. Arterioscler Thromb. 1993;13:900–906.[Abstract/Free Full Text]

31. Jensen JS. Renal and systemic transvascular albumin leakage in severe atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:1324–1329.[Abstract/Free Full Text]

32. Hollenbeck CB, Chen N, Chen YDI, Reaven GM. Relationship between the plasma insulin response to oral glucose and insulin-stimulated glucose utilization in normal subjects. Diabetes. 1984;33:460–463.[Abstract]

33. Groop L, Ekstrand A, Foorsblom C, Widen E, Groop PH, Teppo AM, Eikkson J. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1993;36:642–647.[Medline] [Order article via Infotrieve]

34. Mykkanen L, Zaccaro DJ, O'Leary DH, Howard G, Robbins DC, Haffner SM. Microalbuminuria and carotid intima-media thickness in nondiabetic and NIDDM subjects: the Insulin Resistance Atherosclerosis Study (IRAS). Stroke. 1997;28:1710–1716.[Abstract/Free Full Text]

35. Pedrinelli R, Lindpaintner K, Dell'Omo G, Napoli V, Di Bello V, De Caterina R, Petrucci R. Urinary albumin excretion and atherosclerosis in essential hypertension. Clin Sci. 1997;92:45–50.[Medline] [Order article via Infotrieve]

36. Anderson S, Garcia DL, Brenner BM. Renal and systemic manifestations of glomerular disease. In: Brenner BM, Rector FC, eds. The Kidney. Philadelphia, Pa: Saunders; 1991:1831–1843.

37. Parving HH, Nielsen FS, Bang LE, Smidt UM, Svendsen TL, Chen JW, Gall MA, Rossing P. Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy. Diabetologia. 1996;39:1590–1597.[Medline] [Order article via Infotrieve]

38. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635–641.[Abstract/Free Full Text]

39. Jaffe EA, Nachman RL. Subunit structure of factor VIII antigen synthesized by cultured human endothelial cells. J Clin Invest. 1975;56:698–702.

40. Pedrinelli R, Giampietro O, Carmassi O, Melillo E, Dell'Omo G, Catapano G, Matteucci E, Talarico L, Morale M, De Negri F, Di Bello V. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994;344:14–18.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]

				R. Nosadini, M. Velussi, E. Brocco, C. Abaterusso, F. Piarulli, G. Morgia, A. Satta, R. Faedda, A. Abhyankar, H. Luthman, et al. Altered Transcapillary Escape of Albumin and Microalbuminuria Reflects Two Different Pathogenetic Mechanisms Diabetes, January 1, 2005; 54(1): 228 - 233. [Abstract] [Full Text] [PDF]

				P. Tassani, H. Schad, C. Winkler, A. Bernhard, U. Ettner, S. L. Braun, G. P. Eising, E. Kochs, R. Lange, and J. A. Richter Capillary leak syndrome after cardiopulmonary bypass in elective, uncomplicated coronary artery bypass grafting operations: Does it exist? J. Thorac. Cardiovasc. Surg., April 1, 2002; 123(4): 735 - 741. [Abstract] [Full Text]

				J. S. Jensen, B. Feldt-Rasmussen, S. Strandgaard, M. Schroll, and K. Borch-Johnsen Arterial Hypertension, Microalbuminuria, and Risk of Ischemic Heart Disease Hypertension, April 1, 2000; 35(4): 898 - 903. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pedrinelli, R. Articles by Mariani, M. Search for Related Content PubMed PubMed Citation Articles by Pedrinelli, R. Articles by Mariani, M.